Retatrutide / Cagrilintide (12mg / 3mg)
Retatrutide / Cagrilintide is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (Retatrutide) with a long-acting amylin analog (Cagrilintide).
Researchers use this combination to study the interaction between incretin-receptor signaling and amylin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
$349.99
-
Official retailer
-
Quality guaranteed
-
Free delivery from $99
-
Free returns is available
What Is Retatrutide / Cagrilintide?
Retatrutide / Cagrilintide is a synthetic peptide blend developed for research on complementary metabolic signaling pathways.
Retatrutide is engineered to engage GIP, GLP-1, and glucagon receptors simultaneously. Cagrilintide is an acylated analog of amylin, a pancreatic hormone co-secreted with insulin, designed for extended duration within experimental systems.
Researchers use this blend to investigate how incretin-receptor activation and amylin-receptor activation interact in models of glucose regulation, gastric-emptying signaling, and energy balance.
GENIQ provides this compound solely for controlled laboratory research, not for human or animal use.
Peptide Overview
This blend merges two peptides commonly used in metabolic signaling research:
Retatrutide:
A 39-amino-acid triple agonist studied for its simultaneous activity at GIP, GLP-1, and glucagon receptors and its influence on nutrient-sensing and energy-expenditure models.
Cagrilintide:
A long-acting amylin analog investigated for amylin- and calcitonin-receptor signaling, satiety-circuit modeling, and gastric-emptying regulation in preclinical studies.
| Laboratory studies evaluate how this peptide combination may influence: |
| • Incretin-receptor and amylin-receptor co-activation |
| • Glucose-regulation and glucagon-suppression models |
| • Hypothalamic and brainstem satiety-signaling circuits |
| • Energy-balance pathways in preclinical models |
| These findings are strictly from research environments. |
All findings remain limited to preclinical and in-vitro experimental environments.
History of Retatrutide / Cagrilintide
Cagrilintide was developed as a lipidated amylin analog engineered to resist aggregation and extend duration, building on earlier research with pramlintide and native amylin. Its receptor profile spans amylin and calcitonin receptors.
Retatrutide was developed as a triple agonist, adding glucagon-receptor activity to the GIP/GLP-1 framework used in earlier incretin research.
Researchers began pairing incretin-based peptides with amylin analogs to explore whether the two hormone systems act through complementary mechanisms. The Retatrutide / Cagrilintide combination extends this line of inquiry in in-vitro and preclinical models of metabolic regulation.
Peptide Structure
Retatrutide:
39-amino-acid GIP/GLP-1/glucagon receptor triple agonist with a C20 fatty-diacid side chain
Molecular Formula: C221H342N46O68
Cagrilintide:
Acylated 37-amino-acid amylin analog with a C20 fatty-diacid side chain, incorporating calcitonin-derived residue substitutions for stability
Certificates of Analysis
Retatrutide / Cagrilintide (12mg / 3mg)
Research Findings
Research models analyzing the dual activity of Retatrutide and Cagrilintide commonly explore:
| • Incretin and amylin pathway interactions: Studying combined receptor signaling when both hormone systems are activated. |
| • Glucose-regulation modeling: Examining insulin-secretion, glucagon-suppression, and glucose-disposal responses in preclinical models. |
| • Satiety-circuit signaling: Investigating hypothalamic and area-postrema responses to amylin-receptor activation. |
| • Receptor pharmacology: Assessing binding kinetics, cAMP accumulation, and downstream gene-expression changes in vitro. |
| These data represent controlled in-vitro and preclinical studies, not clinical outcomes. |
These findings reflect laboratory experiments only and do not indicate clinical outcomes.
References
2. Coskun T., et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism, 2022.
3. Kruse T., et al. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” Journal of Medicinal Chemistry, 2021.
4. Lau D.C.W., et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” The Lancet, 2021.
FAQ
What type of research is this peptide blend used for?
It is used to study incretin-receptor and amylin-receptor signaling, glucose-regulation models, and energy-balance pathways.
Does GENIQ provide a Certificate of Analysis?
Yes. Every GENIQ peptide includes a COA verifying identity and purity.
Is this product approved for human or animal use?
No. It is not FDA-approved and not intended for human or veterinary administration.
Can GENIQ provide instructions regarding preparation or use?
No. GENIQ does not give any guidance related to reconstitution, dosing, or application.
Who should handle this compound?
Only trained laboratory researchers in controlled scientific environments.
Research Use Only
All GENIQ compounds are intended strictly for laboratory research.
Not for human or animal consumption, medical use, or therapeutic application.
Nothing in this document should be interpreted as medical advice or as approval for use outside controlled scientific environments.
Retatrutide / Cagrilintide is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (Retatrutide) with a long-acting amylin analog (Cagrilintide).
Researchers use this combination to study the interaction between incretin-receptor signaling and amylin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
Only logged in customers who have purchased this product may leave a review.
RELATED PRODUCTS
Reviews
There are no reviews yet.